Inocras is a bioinformatics-led company redefining precision health through whole-genome data and proprietary analytics. Pulse 2.0 interviewed Inocras co-founder and CEO Jehee Suh to gain a deeper understanding of the company.
Jehee Suh’s Background
Could you please tell me more about your background? Suh said:
“I spent over a decade as a management consultant at McKinsey, primarily working with large pharmaceutical and life sciences companies. My experience afforded me a deep understanding of the industry’s challenges and its immense innovation potential. I made the deliberate decision to transition from advising to actively building. I joined Inocras because I was captivated by the founders’ vision and the transformative power of their technology, using whole-genome data and advanced bioinformatics to redefine how we understand, diagnose, and treat cancer. The potential for impact was enormous, and I have been privileged to lead the company ever since.”
“My responsibility is to ensure that our extraordinary foundation of science and innovation achieves its full potential globally, benefiting clinicians, patients, and researchers. We believe that whole-genome-based insights, leveraging the power of data and bioinformatics, are the future of cancer care. The question is no longer if, but when. And my answer is now.”
“My primary focus is on turning innovation into real-world impact. Optimizing our technology for today’s clinical realities, generating the essential evidence the medical community needs, and clearly communicating our value to the market. This also means building a sustainable, high-growth business model that delivers confidence for our investors. Ultimately, my role is to orchestrate the science, strategy, and execution, but the true engine of this transformation is the exceptional innovation and forward-looking mindset of our dedicated employees.”
Favorite Memory
What has been your favorite memory working for Inocras so far? Suh reflected:
“My favorite moments are when our Innovation Lab members, our R&D unit, say, ‘Give us a couple of weeks.’ In the traditional biomedical world, innovation can take years or even decades to move from an idea to a patient benefit. At Inocras, we operate differently. We are driving biomedical innovation at the speed of IT. Our products are sophisticated algorithms powered by vast amounts of genome data. When our team has a new idea to improve cancer diagnosis or care, they can prototype and deliver a clinical proof of concept within weeks. That agility is truly extraordinary, and it is fundamentally transforming the timeline of medical innovation.”
Core Offerings
What are Inocras’s core offerings? Suh explained:
“Inocras is pioneering whole-genome-based clinical solutions powered by proprietary bioinformatics. In essence, we read and interpret a person’s entire genome to equip doctors with the most comprehensive data to determine the best treatment strategies for genomically driven conditions, such as cancer and rare diseases. Our flagship solutions include:
CancerVision: A whole-genome tumor profiling test that detects all mutation types across the entire genome, providing oncologists with the most complete molecular picture to guide drug selection and treatment strategy.
MRDVision: An ultra-sensitive minimal residual disease (MRD) detection solution powered by WGS and our proprietary ppmSeq™ technology. It allows clinicians to monitor recurrence with unmatched sensitivity and precision, which is critical for post-treatment cancer management.”
Evolution Of The Company’s Technology
How has the company evolved since launching? Suh noted:
“We began in South Korea, but strategically moved our headquarters to San Diego to position ourselves at the center of the global genomics ecosystem. This move was instrumental in building strong relationships with leading hospitals, research centers, and international technology partners.”
“Inocras has evolved from a research-oriented bioinformatics technology company into a leading clinical diagnostics provider, offering highly accurate, standardized, and cost-effective whole-genome solutions for everyday patient care. Looking ahead, the next chapter involves transforming our vast, curated WGS datasets into Cancer Genome Intelligence through the application of advanced AI. Cancer is a disease of the genome, and our comprehensive WGS data allows us to build AI systems that will redefine how cancer is diagnosed, monitored, and treated globally.”
Significant Milestones
What have been some of the company’s most significant milestones? Suh cited:
“Our defining milestone has been bringing whole-genome-based solutions to real-world clinics and patients. Whole-genome sequencing was traditionally confined to research due to its complexity and high cost. Our mission was to change that by making whole-genome-based solutions practical, affordable, and clinically actionable. By leveraging the power of bioinformatics and continuously refining our algorithms with thousands of real patient cases, I am proud to say we have achieved that goal.”
“Today, our tests are fully validated under CAP and CLIA certifications, and more than 200 oncologists, primarily based in Asia, now use our WGS-based tests in their daily clinical practice. With US reimbursement coverage expected within the next six months, we are preparing to bring this critical innovation to patients in the US very soon.”
Customer Success Stories
Can you share any specific customer success stories? Suh highlighted:
“One of our most powerful success stories is a complete ‘Whole-Genome Transformation’ we achieved at a leading cancer center in Asia. We demonstrated to clinicians that our whole-genome solution was not only robust and cost-efficient but also provided far superior clinical utility compared to their conventional NGS targeted panels.”
“As a result, that center transitioned every cancer patient needing a genetic test to our whole-genome platform, adopting a 100% WGS-based standard of care. This dramatic clinical adoption, driven by the excitement and tangible impact seen by the oncologists, led to the volume of tests nearly tripling compared to before. It is a powerful, real-world validation that whole-genome sequencing is ready for routine clinical practice and that it significantly improves clinical actionability for patients.”
Total Addressable Market (TAM)
What total addressable market (TAM) size is the company pursuing? Suh assessed:
“We are focused on the cancer market, which represents a massive and critical opportunity. The US alone accounts for approximately $30 billion in the addressable market for genomic cancer diagnostics and monitoring. Extrapolating globally, that is a rough estimate of a $120 billion total addressable market. This is driven by the fact that our solutions play a critical role in diagnosing and monitoring cancer, the world’s leading cause of death. While tumor profiling is a significant initial market, the more transformative opportunity, as well as a recurring revenue stream, lies in minimal residual disease (MRD) monitoring, which enables both the early detection of cancer recurrence and ongoing treatment optimization.”
Business Goals
What are your business goals heading into 2026? Suh concluded:
“In 2026, our primary business goal is a strategic US clinical expansion. We have achieved strong adoption in Asia and built a robust customer base among leading biopharma partners globally. Up until now, we have been strategically waiting for the ideal timing and regulatory foundation for a full-scale entry into the US clinical market.”
“That inflection point is 2026. With Medicare reimbursement coverage for WGS expected next year, it marks the ideal moment for our clinical expansion in the US. Furthermore, several major medical programs are set to release groundbreaking results in April 2026, which will further validate the clinical power of WGS in cancer care. The oncology world is ready to move beyond limited panels to embrace the full power of the whole genome. For Inocras, 2026 will be the beginning of that transformation and a defining year of growth.”
